This is a Single Center, Open-label Prospective Study to Evaluate the Effect of Xiidra® (Lifitegrast Ophthalmic Solution 5.0%) on Tear Film Biomarkers in Dry Eye

NCT07490535 · clinicaltrials.gov ↗

PHASE4

Phase

NOT_YET_RECRUITING

Status

36

Enrollment

OTHER

Sponsor class

Conditions

Ocular Surface Disease
Dry Eye Syndrome (DES)

Interventions

DRUG: (Xiidra®) Lifitegrast Ophthalmic Solution 5.0%

Sponsor

Pittsburgh Research Institute

Collaborators

[object Object]